top of page
Pipeline_NP top bg.png
Pipeline
MVR-V002

Application

Influenza Therapeutics
Pipeline Overview

Influenza virus is highly likely to mutate, so it cannot be perfectly treated with existing virus inhibitors. MVR-V002 is made by combining sialic acid, which is necessary for the virus to enter host cell, and nanodisc. The sialic acid in MVR-V002 makes virus to misperceive that it has combined with the host cell, resulting the virus to release vRNP into the endosome, not the cell nucleus. The vRNP then becomes completely decomposed by lysosome.

Structure

Small discoidal patch of phospholipid bilayer, using HDL-derived protein as a belt for stabilization

Nanodisc is combined with a cellular receptor

Inhanced stability by improving size and etc.

Nanodisc structure of MVR-V002 alleviating cytotoxicity

•  Cytopathic effect(CPE) reduction assay

in_01.png
Virucidal effect of MVR-V002

•  MVR-V002 penetrating the outer membrane of influenza virus

in_02.png
in_02_1.png

Control : No virus addition

H1N1 : Influenza virus H1N1

ND : Nanodisc

NDTG : Nanodisc with Ganglioside

vRNP eluted from virus, but trapped inside the endosome (Fluorescene microscope)

•  MVR-V002 endocytosed with the virus keeps vRNA from being released into cytoplasm

•  The entrapped vRNA are eventually disassembled by lysosome

in_03.png
bottom of page